AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8316770 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study 3505604 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulb syringe (BLB)
Number of subjects: 60
Study 3505604 — intervention group
Group type: COMPARATOR
Intervention: De Lee catheter (DL)
Number of subjects: 60
Study 29853197 — intervention group
Group type: EXPERIMENTAL
Intervention: Customised titanium CRB omega miniplate
Number of subjects: 200
Study 29853197 — intervention group
Group type: COMPARATOR
Intervention: Conventional titanium miniplates
Number of subjects: 200
Study 27621026 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical suppression of the oscillatory component of reflux
Number of subjects: 54
Study 24319096 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical reminder to providers (intervention group)
Number of subjects: 89
Study 24319096 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 89
Study 22672481 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial risk screening and motivational interviewing intervention
Number of subjects: 42
Study 22672481 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth friendly practice training (9 hours) and feedback
Number of subjects: 42
Study 22672481 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 3 and 12 months post-consultation
Number of subjects: 42
Study 22672481 — intervention group
Group type: COMPARATOR
Intervention: Comparison practices receive a three-hour seminar in youth friendly practice only
Number of subjects: 42
Study 20924261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 or 0.5 mg) monthly + sham PDT
Number of subjects: 423
Study 20924261 — intervention group
Group type: COMPARATOR
Intervention: PDT + monthly sham injection
Number of subjects: 423
Study 20924261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 423
Study 18406949 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic excision
Number of subjects: 72
Study 18406949 — intervention group
Group type: COMPARATOR
Intervention: Open excision
Number of subjects: 72
Study 16371522 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured empathic attention
Number of subjects: 236
Study 16371522 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnotic relaxation
Number of subjects: 236
Study 16371522 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia with fentanyl and midazolam
Number of subjects: 236
Study 16371522 — intervention group
Group type: COMPARATOR
Intervention: Standard care treatment
Number of subjects: 236
Study 16371522 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic analgesia adjuncts
Number of subjects: 236
Study 16371522 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic adjuncts
Number of subjects: 236
Study 11356812 — intervention group
Group type: EXPERIMENTAL
Intervention: Active torso heating with clothing modifications
Number of subjects: 8
Study 11356812 — intervention group
Group type: COMPARATOR
Intervention: Condition 1 (no torso heating)
Number of subjects: 8
Study 11356812 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 2 (moderate torso heating)
Number of subjects: 8
Study 11356812 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 3 (high torso heating)
Number of subjects: 8
Study 11356812 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 4 (extreme torso heating)
Number of subjects: 8
Study 9144368 — intervention group
Group type: EXPERIMENTAL
Intervention: rgp160 on a month 0, 1, 2, 3, 4, and 5 immunization schedule
Number of subjects: 22
Study 9144368 — intervention group
Group type: EXPERIMENTAL
Intervention: rgp160 on a month 0, 1, 2, and 5 schedule
Number of subjects: 22
Study 9144368 — intervention group
Group type: COMPARATOR
Intervention: alum/deoxycholate placebo
Number of subjects: 22
Study 9144368 — intervention group
Group type: COMPARATOR
Intervention: licensed hepatitis B virus vaccine
Number of subjects: 22
Study 9144368 — intervention group
Group type: EXPERIMENTAL
Intervention: rgp160
Number of subjects: 22
Study 7910155 — intervention group
Group type: EXPERIMENTAL
Intervention: nebivolol (5 mg o.i.d.)
Number of subjects: 24
Study 7910155 — intervention group
Group type: COMPARATOR
Intervention: atenolol (100 mg o.i.d.)
Number of subjects: 24
Study 7910155 — intervention group
Group type: EXPERIMENTAL
Intervention: both drugs
Number of subjects: 24
Study 3496284 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 40
Study 3496284 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole
Number of subjects: 40
Study 29794482 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB arm with conventional regimen plus ARB candesartan for the first 6 months (n = 40)
Number of subjects: 77
Study 29794482 — intervention group
Group type: COMPARATOR
Intervention: Control arm with conventional regimen (TSP followed by oral prednisolone) (n = 37)
Number of subjects: 77
Study 29794482 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB arm
Number of subjects: 77
Study 29794482 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 77
Study 26960255 — intervention group
Group type: EXPERIMENTAL
Intervention: Capabilities Model of Dementia Care (CMDC)
Number of subjects: 129
Study 26960255 — intervention group
Group type: COMPARATOR
Intervention: Usual long-term care (LTC)
Number of subjects: 129
Study 22476441 — intervention group
Group type: EXPERIMENTAL
Intervention: QAE-P questionnaire
Number of subjects: 708
Study 21727696 — intervention group
Group type: EXPERIMENTAL
Intervention: Common seborrheic keratosis (CSK)
Number of subjects: 250
Study 21727696 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatosis papulosa nigra (DPN)
Number of subjects: 250
Study 21727696 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedunculated seborrheic keratoses (PSK)
Number of subjects: 250
Study 21727696 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat SK
Number of subjects: 250
Study 21727696 — intervention group
Group type: EXPERIMENTAL
Intervention: Stucco keratoses
Number of subjects: 250
Study 19192368 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatment
Number of subjects: 15
Study 19192368 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatment (patients referred by GP)
Number of subjects: 15
Study 19192368 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatment (patients recruited through systematic screening)
Number of subjects: 15
Study 19192368 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 15
Study 16982961 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP (SBP)
Number of subjects: 1271
Study 16982961 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic BP (DBP)
Number of subjects: 1271
Study 16982961 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean BP (MBP)
Number of subjects: 1271
Study 16982961 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Pressure (PP)
Number of subjects: 1271
Study 15309217 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 11
Study 15309217 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 11
Study 15309217 — intervention group
Group type: COMPARATOR
Intervention: MTX (Methotrexate)
Number of subjects: 11
Study 15309217 — intervention group
Group type: COMPARATOR
Intervention: Control (Healthy blood donors)
Number of subjects: 11
Study 11555394 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART combined with G-CSF thrice weekly for 12 weeks (n = 6)
Number of subjects: 11
Study 11555394 — intervention group
Group type: COMPARATOR
Intervention: HAART (n = 5)
Number of subjects: 11
Study 9233703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (GCV) + Acyclovir (ACV)
Number of subjects: 167
Study 9233703 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir (ACV)
Number of subjects: 167
Study 8292119 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy followed by breast irradiation (50 Gy)
Number of subjects: 818
Study 8292119 — intervention group
Group type: COMPARATOR
Intervention: Lumpectomy alone
Number of subjects: 818
Study 3060987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (4.8 g n‐3 PUFA's) for 12 weeks
Number of subjects: 36
Study 3060987 — intervention group
Group type: COMPARATOR
Intervention: Vegetable oil (4.8 g n‐6 PUFA's) for 12 weeks
Number of subjects: 36
Study 30095673 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure to family members
Number of subjects: 121
Study 30095673 — intervention group
Group type: EXPERIMENTAL
Intervention: Total disclosure
Number of subjects: 121
Study 30095673 — intervention group
Group type: COMPARATOR
Intervention: Disclosure to co-workers, friends, acquaintances, or religious groups
Number of subjects: 121
Study 28751566 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-asparaginase
Number of subjects: 1552
Study 28751566 — intervention group
Group type: COMPARATOR
Intervention: Short-asparaginase
Number of subjects: 1552
Study 25911859 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 μg peginterferon alfa-2a
Number of subjects: 51
Study 25911859 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 μg peginterferon alfa-2a
Number of subjects: 51
Study 24004119 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose helical computed tomography (CT)
Number of subjects: 1000
Study 24004119 — intervention group
Group type: COMPARATOR
Intervention: Chest radiography
Number of subjects: 1000
Study 21345776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.33% delivered at 2 mL/h for 72 hours
Number of subjects: 15
Study 21345776 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% delivered at 2 mL/h for 72 hours (Control)
Number of subjects: 15
Study 18306871 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone
Number of subjects: 30
Study 18306871 — intervention group
Group type: COMPARATOR
Intervention: Serum physiologic
Number of subjects: 30
Study 21092360 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment arm in a RCT for CFS/ME
Number of subjects: 43
Study 15653017 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal Protection (DP) device
Number of subjects: 16
Study 15653017 — intervention group
Group type: COMPARATOR
Intervention: Non-DP group
Number of subjects: 16
Study 12472516 — intervention group
Group type: EXPERIMENTAL
Intervention: Cophenylcaine spray
Number of subjects: 90
Study 12472516 — intervention group
Group type: EXPERIMENTAL
Intervention: No spray
Number of subjects: 90
Study 12472516 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 90
Study 9661597 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior petrosal sinus sampling (IPSS)
Number of subjects: 37
Study 9661597 — intervention group
Group type: COMPARATOR
Intervention: Imaging studies
Number of subjects: 37
Study 7855782 — intervention group
Group type: EXPERIMENTAL
Intervention: Acenocoumarol
Number of subjects: 1700
Study 7855782 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenprocoumon
Number of subjects: 1700
Study 7855782 — intervention group
Group type: EXPERIMENTAL
Intervention: Total INR assessments
Number of subjects: 1700
Study 7855782 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 3 (total observation time assuming INR changing linearly)
Number of subjects: 1700
Study 2729123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol (200, 400, and 800 mg for 5 days)
Number of subjects: 18
Study 2729123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2729123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol
Number of subjects: 18
Study 5312317 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly regimen of high-dosage isoniazid plus streptomycin
Number of subjects: 0
Study 5312317 — intervention group
Group type: COMPARATOR
Intervention: Once-weekly chemotherapy with high-dosage isoniazid plus streptomycin
Number of subjects: 0
Study 5312317 — intervention group
Group type: COMPARATOR
Intervention: Once-weekly chemotherapy with high-dosage isoniazid plus streptomycin plus high-dosage pyrazinamide
Number of subjects: 0
Study 5312317 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial daily phase of 4 weeks with moderate dosage of isoniazid plus streptomycin followed by once-weekly high-dosage isoniazid plus streptomycin
Number of subjects: 0
Study 31122678 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured virtual reality curriculum for laparoscopic appendicectomy (LA)
Number of subjects: 60
Study 31122678 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity VR simulator
Number of subjects: 60
Study 31122678 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 60
Study 29399314 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) in conjunction with 100 mg carbamazepine (administered at baseline and after 2 days) for 9 sessions (3 days a week).
Number of subjects: 30
Study 29399314 — intervention group
Group type: COMPARATOR
Intervention: Sham laser in conjunction with 100 mg carbamazepine (administered at baseline and after 2 days) for 9 sessions (3 days a week).
Number of subjects: 30
Study 28707810 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75-mg GnRHa
Number of subjects: 50
Study 28707810 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.88-mg GnRHa
Number of subjects: 50
Study 25680817 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone (1 g)
Number of subjects: 18
Study 25680817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 23619725 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope (McL) with chest compressions
Number of subjects: 18
Study 23619725 — intervention group
Group type: EXPERIMENTAL
Intervention: AWS (Pentax-AWS Airwayscope) with chest compressions
Number of subjects: 18
Study 20582425 — intervention group
Group type: EXPERIMENTAL
Intervention: IMN plus misoprostol
Number of subjects: 290
Study 20582425 — intervention group
Group type: COMPARATOR
Intervention: misoprostol plus placebo
Number of subjects: 290
Study 18813182 — intervention group
Group type: COMPARATOR
Intervention: Lercanidipine
Number of subjects: 16
Study 18813182 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine and antioxidants (Vitamins C and E)
Number of subjects: 16
Study 16543714 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (TIW)
Number of subjects: 220
Study 16543714 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (QD)
Number of subjects: 220
Study 16543714 — intervention group
Group type: COMPARATOR
Intervention: Placebo (TIW)
Number of subjects: 220
Study 16543714 — intervention group
Group type: COMPARATOR
Intervention: Placebo (QD)
Number of subjects: 220
Study 14526263 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed AA solution infusion at low rate (2 mg/min/kg BW)
Number of subjects: 8
Study 14526263 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed AA solution infusion at high rate (4.5 mg/min/kg BW)
Number of subjects: 8
Study 14526263 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline infusion (control)
Number of subjects: 8
Study 11070529 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term alcohol-focused intervention (six 1-hour sessions)
Number of subjects: 32
Study 11070529 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 32
Study 8982557 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophane dialyzer
Number of subjects: 36
Study 8982557 — intervention group
Group type: COMPARATOR
Intervention: Polymethylmethacrylate (PMMA) dialyzer
Number of subjects: 36
Study 1468827 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 48-h infusion of calcitonin gene-related peptide (n = 6)
Number of subjects: 11
Study 1468827 — intervention group
Group type: EXPERIMENTAL
Intervention: Two successive 8-h infusions of calcitonin gene-related peptide (n = 5)
Number of subjects: 11
Study 1468827 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 48-h infusion of calcitonin gene-related peptide
Number of subjects: 11
Study 6742081 — intervention group
Group type: EXPERIMENTAL
Intervention: d-timolol
Number of subjects: 34
Study 6742081 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study 29996735 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh angular velocity ratios
Number of subjects: 21
Study 27742624 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused ultrasound examination (f‐US) of the heart and lungs performed by emergency physicians (EP) as soon as the patient arrives to the emergency department (ED)
Number of subjects: 288
Study 27742624 — intervention group
Group type: COMPARATOR
Intervention: Standard diagnostic evaluation by the EP
Number of subjects: 288
Study 26557703 — intervention group
Group type: EXPERIMENTAL
Intervention: Family‐ and safety‐supportive supervisor behavior training (computer‐based), followed by two weeks of behavior tracking and a four‐hour, facilitated team effectiveness session including supervisors and employees.
Number of subjects: 264
Study 26557703 — intervention group
Group type: EXPERIMENTAL
Intervention: Family‐and safety‐supportive supervisor behavior training (computer‐based), followed by two weeks of behavior tracking and a four‐hour, facilitated team effectiveness session including supervisors and employees.
Number of subjects: 264
Study 23053266 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinational therapy (vinorelbine and capecitabine)
Number of subjects: 60
Study 23053266 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy (vinorelbine followed by capecitabine)
Number of subjects: 60
Study 23053266 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinational therapy (vinorelbine and capecitabine) in patients with liver metastases
Number of subjects: 60
Study 20968019 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined photon-neutron radiotherapy (CPNT)
Number of subjects: 31
Study 20968019 — intervention group
Group type: COMPARATOR
Intervention: Photon therapy
Number of subjects: 31
Study 18233965 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular premature complex (VPC)
Number of subjects: 29
Study 18233965 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-long-short (SLS) sequence
Number of subjects: 29
Study 18233965 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SLS only
Number of subjects: 29
Study 18233965 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with VPC only
Number of subjects: 29
Study 18233965 — intervention group
Group type: COMPARATOR
Intervention: ECG parameters
Number of subjects: 29
Study 16608061 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D texture classification using adaptive multiple feature method (AMFM)
Number of subjects: 34
Study 16608061 — intervention group
Group type: COMPARATOR
Intervention: 2-D texture classification using adaptive multiple feature method (AMFM)
Number of subjects: 34
Study 16608061 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D classification of NN vs NS
Number of subjects: 34
Study 16608061 — intervention group
Group type: COMPARATOR
Intervention: 2-D classification of NN vs NS
Number of subjects: 34
Study 15214555 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (40 patients randomized)
Number of subjects: 85
Study 15214555 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-left ductal shunt
Number of subjects: 85
Study 15214555 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-right ductal shunt
Number of subjects: 85
Study 15214555 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-right atrial shunt
Number of subjects: 85
Study 11702913 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 8
Study 11702913 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose)
Number of subjects: 8
Study 9209202 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 19
Study 9209202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8129324 — intervention group
Group type: EXPERIMENTAL
Intervention: Proparacaine HCl 0.5% eye drops
Number of subjects: 55
Study 8129324 — intervention group
Group type: COMPARATOR
Intervention: Normal saline eye drops
Number of subjects: 55
Study 3620098 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (0 g/kg, 0.12 g/kg, 0.6 g/kg, 1.05 g/kg lean body weight)
Number of subjects: 0
Study 3620098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (higher doses)
Number of subjects: 0
Study 3620098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 0
Study 30962103 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG (5-7 mg/kg/day) + Cognitive Training (CT)
Number of subjects: 27
Study 30962103 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Cognitive Training (CT)
Number of subjects: 27
Study 29742136 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA plus food (10 kg/month of fortified wheat-soya 'Super Cereal')
Number of subjects: 25092
Study 29742136 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA only
Number of subjects: 25092
Study 29742136 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA plus cash (NPR750≈US$7.5/month)
Number of subjects: 25092
Study 29742136 — intervention group
Group type: COMPARATOR
Intervention: Control (existing government programmes)
Number of subjects: 25092
Study 29742136 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA plus cash
Number of subjects: 25092
Study 29742136 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA plus food
Number of subjects: 25092
Study 26820618 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (3-6 ng/mL) with reduced-exposure calcineurin inhibitor (CNI; cyclosporine) to weeks 7-11 after transplant, followed by increased everolimus exposure (target 6-10 ng/mL) with cyclosporine withdrawal
Number of subjects: 115
Study 26820618 — intervention group
Group type: COMPARATOR
Intervention: Standard-exposure cyclosporine
Number of subjects: 115
Study 26820618 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 115
Study 26820618 — intervention group
Group type: COMPARATOR
Intervention: CNI-treated patients
Number of subjects: 115
Study 26215945 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 2923
Study 26215945 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 2923
Study 23896830 — intervention group
Group type: COMPARATOR
Intervention: Mild therapeutic hypothermia (target temperature of 33°C) alone (n=17)
Number of subjects: 36